IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020
IDEAYA Biosciences (Nasdaq: IDYA) announced its participation in two investor conferences in August 2020. CEO Yujiro S. Hata will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 11 at 1:00 pm EST. He will also participate in the Wedbush PacGrow Healthcare Virtual Conference on August 12 at 8:00 am EST, discussing his recent report on synthetic lethality in cancer. Live webcasts will be available on IDEAYA's website, with replays accessible for 30 days afterward.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the Company will participate in the following upcoming investor conferences:
!["(PRNewsfoto/IDEAYA]("https://mma.prnewswire.com/media/820568/IDEAYA_Logo.jpg" "\"(PRNewsfoto/IDEAYA"){kind=logo}
- BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 1:00 pm EST. Yujiro S. Hata, Chief Executive Officer and President, IDEAYA Biosciences, will participate in a fireside chat with Thomas Shrader, Ph.D., CFA, Equity Research Analyst, BTIG
- Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 8:00 am EST. Yujiro S. Hata, Chief Executive Officer and President, IDEAYA Biosciences, will participate in a fireside chat with Robert Driscoll, Ph.D., Equity Research Analyst, Wedbush, including to discuss his recent industry report entitled "Exploiting Addiction: A Review of Synthetic Lethality in Cancer"
A live audio webcast of each presentation will be available by visiting the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/news-events/investor-calendar. A replay of the webcasts will be available for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on May 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
!["Cision"]("https://c212.net/c/img/favicon.png?sn=AQ62397&sd=2020-07-14" "\"Cision\"")
View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-to-participate-in-fireside-chat-at-btig-biotechnology-conference-and-wedbush-pacgrow-healthcare-conference-on-august-11-and-12-2020-301092618.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What conferences will IDEAYA Biosciences participate in during August 2020?
Who is the CEO of IDEAYA Biosciences?
What topics will be discussed at the investor conferences for IDEAYA?
When can I watch the live webcasts for IDEAYA's investor conferences?
What is the significance of synthetic lethality for IDEAYA Biosciences?
